Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: Beyond clopidogrel

Current Medical Research and Opinion

Volumn 28, Issue 2, 2012, Pages 203-211

  Jukema, J Wouter ^a   Collet, Jean Philippe ^b   De Luca, Leonardo ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c EUROPEAN HOSPITAL   (Italy)

Author keywords

Acute coronary syndromes; Antiplatelet drugs; Clopidogrel; Myocardial revascularisation; Prasugrel; ST elevated myocardial infarction; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; TICAGRELOR;

BLEEDING; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADENOSINE; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES; TICLOPIDINE;

EID: 84856487148     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.651526     Document Type: Review

References (27)

1. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31:2501-55
2. Eitel I, Franke A, Schuler G, et al. ST-segment resolution and prognosis after facilitated versus primary percutaneous coronary intervention in acute myocardial infarction: a meta-analysis. Clin Res Cardiol 2010;99:1-11
3. Grosgurin O, Plojoux J, Keller PF, et al. Prehospital emergency physician activation of interventional cardiology team reduces door-to-balloon time in ST-elevation myocardial infarction. Swiss Med Wkly 2010;140:228-32
4. Le May MR, Dionne R, Maloney J, et al. The role of paramedics in a primary PCI program for ST-elevation myocardial infarction. Prog Cardiovasc Dis 2010;53:183-7
5. Prati F, Petronio S, Van Boven AJ, et al. FINESSE-ANGIO substudy investigators. Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events-Angiographic) study. JACC Cardiovasc Interv 2010;3: 1284-91
6. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122:2131-41
7. Norgard NB, Abu-Fadel M. Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc Health Risk Manag 2009;5:873-82
8. Agewall S, Badimon L, Drouet L, et al. Oral antiplatelet agents in ACS: from pharmacology to clinical differences. Fundam Clin Pharmacol 2011; 25:564-71
9. Wilson W, Gurvitch R, Ajani AE. Prasugrel: a novel platelet ADP P2Y receptor antagonist. Cardiovasc Ther 2009;27:194-8
10. Siddique A, Butt M, Shantsila E, et al. New antiplatelet drugs: beyond aspirin and clopidogrel. Int J Clin Pract 2009;63:776-89
11. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29:21-30
12. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116:2923-32 (Pubitemid 350291199)
13. Wiviott SD, Braunwald E, McCabe CH. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15 (Pubitemid 350106708)
14. O'Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol 2009;54:678-85
15. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-31
16. Murphy SA, Antman EM, Wiviott SD, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008; 29:2473-9
17. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-51 (Pubitemid 350007959)
18. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375:283-93
19. Pocock SJ, Mehran R, Clayton TC, et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2010;121:43-51
20. Biondi-Zoccai G, Lotrionte M, Agostoni P. Adjusted indirect comparison metaanalysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol 2011;150:325-31
21. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-36 (Pubitemid 350154353)
22. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320-8
23. Amin AP, Marso SP. Acute coronary syndrome in the patient with diabetes: is the management different? Curr Cardiol Rep 2010;12:321-9
24. Bagust A, Hopkinson PK, Maslove L, et al. Estimated growth in type 2 diabetes and US population from 2000-2050. Diabetes 2010;50: A205 838-p
25. Bartnik M, Rydén L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. European Heart Journal 2004; 25:1880-90 (Pubitemid 39452604)
26. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010;31:3006-16
27. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-36